Here we present AB-201, an off-the-shelf, cryopreserved cord blood (CB) derived HER2-CAR NK cell therapy with the potential to be an active and readily available option for patients with HER2+ solid tumors.

AB-201 is an allogeneic anti-HER2 CAR-NK cell product candidate, containing a CAR with a proprietary HER2 antigen recognition domain and expressing soluble IL-15.

2024年8月6日 · The U.S. military completed its withdrawal from Air Base 201 in Agadez, Aug. 5. The departure from AB 201 was completed more than a month ahead of schedule and was facilitated by the transparency and professionalism of both U.S. and Nigerien forces.

2022年9月20日 · AB-201 is an allogeneic HER2-targeted chimeric antigen receptor NK (CAR-NK) cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing.

Here we present AB-201, an off-the-shelf, cryopreserved cord blood (CB)-derived HER2 chimeric antigen receptor (CAR)-natural killer (NK) cell therapy as a safe, active, and readily available option for patients with HER2+ solid tumors.

2023年8月16日 · AlloNK ® (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal...

2024年1月8日 · AB-201 is an allogeneic HER2-targeted chimeric antigen receptor NK (CAR-NK) cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing.

2021年10月21日 · AB-201 is an allogeneic anti-HER2 CAR-NK cell therapy candidate manufactured from cord blood, containing a proprietary HER2 antigen recognition domain. Artiva is developing AB-201 for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers.

Atlantic Blowers' AB-201 Single Phase/Single Stage Regenerative Blower can be used for various pressure or vacuum applications. The AB-201 produces a maximum flow of 110 CFM.

A novel, high affinity anti-HER2 antibody converted to scFv structure confers highly specific tumor targeting and is coupled with a unique costimulatory structure and IL-15 expression for enhanced activity and persistence. AB-201 has demonstrated potent anti-tumor activity in multiple preclinical HER2-positive tumor model systems.